Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals

Health Policy

Volumn 81, Issue 2-3, 2007, Pages 376-384

  Andersson, Karolina ^a   Bergström, Gina ^a   Petzold, Max G ^b,c   Carlsten, Anders ^a,d  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^d Apoteket AB   (Sweden)

Author keywords

Generic substitution; Health care reform; Patient co payment; Pharmaceutical benefits scheme; Pharmaceutical expenditure; Reimbursed cost

Indexed keywords

GENERIC DRUG;

ARTICLE; CONSUMER; DRUG COST; DRUG MARKETING; DRUG SUBSTITUTION; HEALTH INSURANCE; HOSPITAL PHARMACY; HUMAN; OUTPATIENT CARE; PHARMACY; POLICY; PRESCRIPTION; REIMBURSEMENT; SWEDEN;

COST CONTROL; DRUG COSTS; DRUGS, GENERIC; FINANCING, PERSONAL; HEALTH CARE REFORM; HEALTH EXPENDITURES; HUMANS; STATE MEDICINE; SWEDEN; THERAPEUTIC EQUIVALENCY;

EID: 33947267465     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2006.07.005     Document Type: Article

References (37)

1. Gerdtham U.G., and Lundin D. Why did drug spending increase during the 1990s? A decomposition based on Swedish data. Pharmacoeconomics 22 1 (2004) 29-42
2. Ljungkvist M.O., Andersson D., and Gunnarsson B. Cost and utilisation of pharmaceuticals in Sweden. Health Policy 41 Suppl (1997) S55-S69
3. Andersson K., Petzold M., Sonesson C., Lonnroth K., and Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 79 (2006) 231-243
4. Liu S.Z., and Romeis J.C. Changes in drug utilization following the outpatient prescription drug cost-sharing program-evidence from Taiwan's elderly. Health Policy 68 3 (2004) 277-287
5. McManus P., Donnelly N., Henry D., Hall W., Primrose J., and Lindner J. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiology and Drug Safety 5 6 (1996) 385-392
6. Soumerai S.B., Avorn J., Ross-Degnan D., and Gortmaker S. Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. New England Journal of Medicine 317 9 (1987) 550-556
7. Tamblyn R., Laprise R., Hanley J.A., Abrahamowicz M., Scott S., Mayo N., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285 4 (2001) 421-429
8. Winkelmann R. Co-payments for prescription drugs and the demand for doctor visits-evidence from a natural experiment. Health Economics 13 11 (2004) 1081-1089
9. Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 67 2 (2004) 149-165
10. Ghislandi S., Krulichova I., and Garattini L. Pharmaceutical policy in Italy: towards a structural change?. Health Policy 72 1 (2005) 53-63
11. Fattore G., and Jommi C. The new pharmaceutical policy in Italy. Health Policy 46 1 (1998) 21-41
12. Drummond M., Jönsson B., and Rutten F. The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40 3 (1997) 199-215
13. Salkeld G., Mitchell A., and Hill S. Pharmaceuticals. In: Mooney G., and Scotton R. (Eds). Economics and Australian health policy (1998), Allen & Unwin, Sydney 309
14. Birkett D.J., Mitchell A.S., and McManus P. A cost-effectivness approach to drug subsidy and pricing in Australia. Health Affairs 20 3 (2001) 104-114
15. Giuliani G., Selke G., and Garattini L. The German experience in reference pricing. Health Policy 44 1 (1998) 73-85
16. Ioannides-Demos L.L., Ibrahim J.E., and McNeil J.J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 20 9 (2002) 577-591
17. Schneeweiss S., Schöffski O., and Selke G.W. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy 44 3 (1998) 253-260
18. Schneeweiss S., Soumerai S.B., Glynn R.J., Maclure M., Dormuth C., and Walker A.M. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. Canadian Medical Association Journal 166 6 (2002) 737-745
19. Schneeweiss S., Dormuth C., Grootendorst P., Soumerai S.B., and Maclure M. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Medical Care 42 7 (2004) 653-660
20. Rafferty T., Wilson-Davis K., and McGavock H. How has fundholding in Northern Ireland affected prescribing patterns? A longitudinal study. British Medical Journal 315 7101 (1997) 166-170
21. Dowell J.S., Snadden D., and Dunbar J.A. Changing to generic formulary: how one fundholding practice reduced prescribing costs. British Medical Journal 310 6978 (1995) 505-508
22. Kanavos P., and Mossialos E. Outstanding regulatory aspects in the European pharmaceutical market. Pharmacoeconomics 15 6 (1999) 519-533
23. Boersma C., Klok R.M., Bos J.M., Naunton M., van den Berg P.B., de Jong-van den Berg L.T., et al. Drug costs developments after patent expiry of enalapril, fluoxetine and ranitidine: a study conducted for The Netherlands. Applied Health Economics Health Policy 4 3 (2005) 191-196
24. McManus P., Birkett D.J., Dudley J., and Stevens A. Impact of the minimum pricing policy and introduction of brand (generic) substitution into the pharmaceutical benefits scheme in Australia. Pharmacoepidemiology and Drug Safety 10 4 (2001) 295-300
25. Morgan S.G., Agnew J.D., and Barer M.L. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. Health Policy 68 3 (2004) 299-307
26. Tootelian D.H., Royer J., and Johnson R.C. Providing incentives to control health care costs and remain competitive in the marketplace: a pilot study. Health Marketing Quarterly 15 2 (1997) 87-99
27. Andersson K., Sonesson C., Petzold M., Carlsten A., and Lönnroth K. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiology and Drug Safety 14 5 (2005) 341-348
28. Garattini L., and Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 51 3 (2000) 149-162
29. Fischer M.A., and Avorn J. Economic consequences of underuse of generic drugs: evidence from medicaid and implications for prescription drug benefit plans. Health Services Research 38 4 (2003) 1051-1063
30. Fischer M.A., and Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiology and Drug Safety 13 4 (2004) 207-214
31. Smith D.G. The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry 30 2 (1993) 189-198
32. Hoffmann M. Drug Reform in Sweden. Major changes for patients, doctors and healthcare managers. Hospital-the Official Journal of the European Association of Hospital Managers 2004;1.
33. Act (2002:160) on Pharmaceutical Benefits, etc. SFS; 2002.
34. Statistiska Centralbyrån. The Swedish consumer price index: a handbook of methods. Stockholm; Örebro: Statistiska centralbyrån (SCB); 2001.
35. Utbyte av läkemedel-En uppföljning av de de första 15 månaderna med läkemedelsreformen. Report: Apoteket AB, Landstingsförbundet, Läkemedelsförmånsnämnden; 2004.
36. Simoens S., De Bruyn K., Bogaert M., and Laekeman G. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 23 8 (2005) 755-766
37. Granlund D., Rudholm N., and Wikstrom M. Fixed budgets as a cost containment measure for pharmaceuticals. European Journal of Health Economics (2006)